The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer

Cancer Research

Volumn 63, Issue 2, 2003, Pages 337-341

  Foekens, John A ^a,c   Ries, Christian ^b   Look, Maxime P ^a   Gippner Steppert, Cornelia ^b   Klijn, Jan G M ^a   Jochum, Marianne ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; LEUKOCYTE ELASTASE; METHOTREXATE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CELL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ASSAY; ENZYME MECHANISM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; RISK ASSESSMENT; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKOCYTE ELASTASE; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037439962     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jänicke, F., Prechtl, A., Thomssen, C., Harbeck, N., Meisner, C., Untch, M., Sweep, C. G. J., Selbman, H-K., Graeff, H., and Schmitt, M. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl. Cancer Inst. (Bethesda), 93: 913-920, 2001.
2. Look, M. P., van Putten, W. L. J., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Fernö M., Eppenberger-Castori, S., Sweep, C. G. J., Ulm, K., Peyrat, J. P., Martin, P. M., Magdelenat, H., Brünner, N., Duggan, C., Lisboa, B. W., Bendahl, P. O., Quillien, V., Daver, A., Ricolleau, G., Meijer-van Gelder, M. E., Manders, P., Fiets, W. E., Blankenstein, M. A., Broët, P., Romain, S., Daxenbichler, G., Windbichler, G., Cufer, T., Borstnar, S., Kueng, W., Beex, L. V. A. M., Klijn, J. G. M., O'Higgins, N., Eppenberger, U., Jänicke, F., Schmitt, M., and Foekens, J. A. Pooled analysis of prognostic impact of urokinase-type plasminogen activators and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. (Bethesda), 94: 116-128, 2002.
3. 3 binding to vitronectin? Nature (Lond.), 383: 441-443, 1996.
4. Bajou, K., Noël, A., Gerard, R. D., Masson, V., Brünner, N., Holst-Hansen, C., Skobe, M., Füsenig, N. E., Carmeliet, P., Collen, D., and Foidart, J. M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med., 4: 923-928, 1998.
5. Wu, K., Urano, T., Ihara, H., Takada, Y., Fujie, M., Shikimori, M., Hashimoto, K., and Takada, A. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: the evaluation of its physiologic relevance in fibrinolysis. Blood, 86: 1056-1061, 1995.
6. Gramse, M., Egbring, R., and Havemann, K. α2-plasmin inhibitor inactivation by granulocyte elastase. Hoppe-Seyler's Z. Physiol. Chem., 356: 19-26, 1984.
7. Barrett, A. J. Leukocyte elastase. Methods Enzymol., 80: 581-588, 1981.
8. Yamashita, J-I., Ogawa, M., Ikei, S., Omachi, H., Yamashita, S-I., Saishoji, T., Nomura, K., and Sato, H. Production of immunoreactive polymorphonuclear leukocyte elastase in human breast cancer cells: possible role of polymorphonuclear leukocyte in the progression of human breast cancer. Br. J. Cancer, 69: 72-76, 1994.
9. Yamashita, J-I., Ogawa, M., and Shirakusa, T. Free-form neutrophil elastase is an independent marker predicting recurrence in primary breast cancer. J. Leukocyte Biol., 57: 375-378, 1995.
10. Yamashita, J-I., Ogawa, M., and Sato, K. Prognostic significance of three novel biological factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery, 117: 601-608, 1995.
11. Foekens, J. A., Portengen, H., van Putten, W. L. J., Peters, H. A., Krijnen, H. L. J. M., Alexieva-Figusch, J., and Klijn, J. G. M. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res., 49: 5823-5828, 1989.
12. Foekens, J. A., Peters, H. A., Look, M. P., Portengen, H., Schmitt, M., Kramer, M. D., Brünner, N., Jänicke, F., Meijer-van Gelder, M. E., Henzen-Logmans, S. C., van Putten, W. L. J., and Klijn, J. G. M. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res., 60: 636-643, 2000.
13. Jänicke, F., Schmitt, M., Hafter, R., Hollreider, A., Babic, R., Ulm, K., Gössner, W., and Graeff, H. Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis, 4: 69-78, 1990.
14. Barlow, R. E., Bartholomew, D. J., Bremner, J. M., and Brunck, H. D. Statistical Inference under Order Restrictions. New York: John Wiley & Sons, Inc., 1972.
15. Grambsch, P. M., and Therneau, T. M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika, 81: 515-526, 1994.
16. Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H., Kemeny, N. E., Jessup, J. M., Locker, G. Y., Macdonald, J. S., Mennel, R. G., Norton, L., Ravdin, P., Taube, S., and Winn, R. J. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst. (Bethesda), 88: 1456-1466, 1996.
17. Kao, R. T., and Stern, R. Elastases in human breast carcinoma cell lines. Cancer Res., 46: 1355-1358, 1986.
18. Machovich, R., and Owen, W. G. An elastase-dependent pathway of plasminogen activation. Biochemistry, 28: 4517-4522, 1989.
19. Hilsenbeck, S. G., Ravdin, P. M., de Moor, C. A., Chamness, G. C., Osborne, C. K., and Clark, G. M. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res. Treat., 52: 227-237, 1998.
20. Inada, M., Yamashita, J-L. Nakano, S., and Ogawa, M. Complete inhibition of spontaneous pulmonary metastasis of human lung carcinoma all line EBC-1 by a neutrophil elastase inhibitor (ONO-5046-Na). Anticancer Res., 18: 885-890, 1998.